Esperion Therapeutics Newsroom

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsNov 26 23:32

Esperion Therapeutics Analyst Ratings

BenzingaNov 19 19:39

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsNov 19 19:31

A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16

Futu NewsNov 8 21:14

BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating

Futu NewsOct 28 22:31

Esperion Therapeutics Analyst Ratings

BenzingaOct 2 22:48

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Futu NewsOct 2 22:33

JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $7

Futu NewsSep 3 23:32

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

BenzingaAug 13 01:57

Esperion Therapeutics Analyst Ratings

BenzingaAug 13 01:55

BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating

Futu NewsJul 30 21:54

Esperion Therapeutics Analyst Ratings

BenzingaJun 28 23:10

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

BenzingaJun 28 23:09

Esperion Therapeutics Analyst Ratings

BenzingaJun 20 18:39

B of A Securities Downgrades Esperion Therapeutics to Underperform, Lowers Price Target to $2.5

BenzingaJun 20 18:37

Esperion Therapeutics Analyst Ratings

BenzingaMay 23 00:07

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

BenzingaMay 23 00:00

HC Wainwright & Co. : The Esperion Therapeutics (ESPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.

Zhitong FinanceMay 21 17:51

Esperion Therapeutics Analyst Ratings

BenzingaMay 21 17:45

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

BenzingaMay 21 17:45